FORM 4 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940 |
|
|||||||||||||||
Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b). |
1. Name and Address of Reporting Person*
(Street)
|
2. Issuer Name and Ticker or Trading Symbol
AbCellera Biologics Inc. [ ABCL ] |
5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)
|
||||||||||||||||||||||||
3. Date of Earliest Transaction
(Month/Day/Year) 06/18/2021 | ||||||||||||||||||||||||||
4. If Amendment, Date of Original Filed
(Month/Day/Year) |
6. Individual or Joint/Group Filing (Check Applicable Line)
|
Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned | ||||||||||
---|---|---|---|---|---|---|---|---|---|---|
1. Title of Security (Instr. 3) | 2. Transaction Date (Month/Day/Year) | 2A. Deemed Execution Date, if any (Month/Day/Year) | 3. Transaction Code (Instr. 8) | 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) | 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) | 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 7. Nature of Indirect Beneficial Ownership (Instr. 4) | |||
Code | V | Amount | (A) or (D) | Price | ||||||
Common Shares | 06/18/2021 | J(1) | 5,000,000 | D | $0.00(1) | 24,105,761 | I | See Footnote(2)(3) | ||
Common Shares | 06/18/2021 | J(1) | 73,892 | A | $0.00(1) | 73,892 | I | See Footnote(4)(5) |
Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities) | |||||||||||||||
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
1. Title of Derivative Security (Instr. 3) | 2. Conversion or Exercise Price of Derivative Security | 3. Transaction Date (Month/Day/Year) | 3A. Deemed Execution Date, if any (Month/Day/Year) | 4. Transaction Code (Instr. 8) | 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) | 6. Date Exercisable and Expiration Date (Month/Day/Year) | 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) | 8. Price of Derivative Security (Instr. 5) | 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) | 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) | 11. Nature of Indirect Beneficial Ownership (Instr. 4) | ||||
Code | V | (A) | (D) | Date Exercisable | Expiration Date | Title | Amount or Number of Shares |
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
| ||||||||||||||||||||||||
1. Name and Address of Reporting Person*
(Street)
Relationship of Reporting Person(s) to Issuer
|
Explanation of Responses: |
1. On June 18, 2021, DCVC Bio, L.P. ("DCVC Bio") distributed, for no consideration, an aggregate of 5,000,000 Common Shares of the Issuer ("DCVC Bio Shares") to its limited partners and to DCVC Bio GP, LLC ("DCVC Bio GP"), its general partner, representing each such partner's pro rata interest in such DCVC Bio Shares. All of the aforementioned distributions were made in accordance with the exemptions afforded by Rules 16a-13 and 16a-9 of the Securities Exchange Act of 1934, as amended. |
2. These securities are held by DCVC Bio. DCVC Bio GP is the general partner of DCVC Bio and has sole voting and dispositive power with regard to the securities held by DCVC Bio. JNK Capital Management, LLC ("JNK") and ZNM Capital Management, LLC ("ZNM") are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio. |
3. (Continued from Footnote 2) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any. |
4. These securities are held by DCVC Bio GP. JNK and ZNM are the managing members of DCVC Bio GP and share voting and dispositive power with respect to the securities held by DCVC Bio GP. The managing members of JNK and ZNM are Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead. Matthew Ocko, Zachary Bogue, John Hamer and Kiersten Stead share voting and dispositive power with respect to the securities held by DCVC Bio GP. |
5. (Continued from Footnote 4) Each of the Reporting Persons disclaims the existence of a "group" and disclaims beneficial ownership of such securities and this report shall not be deemed an admission that it is the beneficial owner of such securities, except to the extent of its indirect pecuniary interest therein, if any. |
Remarks: |
This is one of two Form 4s filed on the date hereof in respect of these securities. The Reporting Person for the other Form 4 is John Hamer. |
DCVC Bio, L.P. By: DCVC Bio GP, LLC Its: General Partner By: ZNM Capital Management, LLC Its: Managing Member By: /s/ Matthew Ocko Matthew Ocko, Managing Member | 06/21/2021 | |
DCVC Bio GP, LLC, By: ZNM Capital Management, LLC Its: Managing Member By: /s/ Matthew Ocko Matthew Ocko, Managing Member | 06/21/2021 | |
JNK Capital Management, LLC, By: /s/ Kiersten Stead Kiersten Stead, Managing Member | 06/21/2021 | |
ZNM Capital Management, LLC By: /s/ Matthew Ocko Matthew Ocko, Managing Member | 06/21/2021 | |
Zachary Bogue /s/ Zachary Bogue | 06/21/2021 | |
Matthew Ocko /s/ Matthew Ocko | 06/21/2021 | |
Kiersten Stead /s/ Kiersten Stead | 06/21/2021 | |
** Signature of Reporting Person | Date | |
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly. | ||
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v). | ||
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a). | ||
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure. | ||
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number. |